- Singulex Ultrasensitive Immunoassay for Cardiotoxicity Testing at SOT 2012
Product News: Singulex Ultrasensitive Immunoassay for Cardiotoxicity Testing at SOT 2012Singulex will be featuring a highly sensitive Cardiac Troponin I (cTnI) immunoassay kit for preclinical toxicity and safety assessment at the Society of Toxicology meeting in San Francisco CA.
Cardiotoxicity alerts and recent drug recalls have generated concerns for regulatory agencies and pharmaceutical companies. As a result there is an increased pressure to implement more sensitive detection methods that allow for early and robust cardiotoxicity assessment during drug development.
To address this unmet need, Singulex has applied its proprietary high-definition single-molecule counting technology towards commercialization of an ultrasensitive cTnI Immunoassay. The assay’s superior sensitivity enables the true range of cTnI in a reference population to be established, allowing drug-induced cardiotoxicity to be accurately assessed. The Erenna® cTnI Immunoassay Kit offers:
• Unprecedented assay sensitivity with a lower limit of quantification (LLoQ) of 0.4 pg/mL.
• Robust detection of cTnI at low basal levels with tight CV%s.
• Low sample consumption, using only 20 µL per singlet sample tested.
Visit Booth #1637 at ToxExpo 2012 to learn more about the power of high-definition Singulex immunoassays!
Or attend the following Singulex hosted session and enter for a chance to win a Kindle Fire: Applications of Ultrasensitive Immunoassay Technology for Pre-Clinical Toxicity Testing
Date: Monday, March 12
Time: 2:15 PM–3:15 PM
Location: Room 100, Moscone South
Presented by: Dr. Lynn Zieske, VP of Commercial Solutions, Singulex. email@example.com
Abstract: Drug safety and toxicity testing often requires precise monitoring of biomarker response, but analytical methods capable of providing the requisite sensitivity and dynamic range are lacking. The talk presents an ultrasensitive immunoassay technology and how it improves biomarker utility in pre-clinical testing.